BECTON DICKINSON AND CO (BDX) Stock Price, Forecast & Analysis

NYSE:BDX • US0758871091

182.49 USD
-1.85 (-1%)
At close: Feb 24, 2026
182.49 USD
0 (0%)
After Hours: 2/24/2026, 8:10:21 PM

BDX Key Statistics, Chart & Performance

Key Statistics
Market Cap51.99B
Revenue(TTM)21.92B
Net Income(TTM)1.76B
Shares284.91M
Float283.76M
52 Week High235.34
52 Week Low162.29
Yearly Dividend4.16
Dividend Yield2.3%
EPS(TTM)13.9
PE13.13
Fwd PE11.58
Earnings (Next)04-29
IPO1963-09-25
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
BDX short term performance overview.The bars show the price performance of BDX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10

BDX long term performance overview.The bars show the price performance of BDX in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20

The current stock price of BDX is 182.49 USD. In the past month the price decreased by -10.29%. In the past year, price decreased by -19.08%.

BECTON DICKINSON AND CO / BDX Daily stock chart

BDX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
BDX Full Technical Analysis Report

BDX Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to BDX. BDX has an excellent profitability rating, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BDX Full Fundamental Analysis Report

BDX Financial Highlights

Over the last trailing twelve months BDX reported a non-GAAP Earnings per Share(EPS) of 13.9. The EPS decreased by -0.07% compared to the year before.


Industry RankSector Rank
PM (TTM) 8.01%
ROA 3.2%
ROE 6.95%
Debt/Equity 0.67
Chartmill High Growth Momentum
EPS Q2Q%-15.16%
Sales Q2Q%1.63%
EPS 1Y (TTM)-0.07%
Revenue 1Y (TTM)6.22%
BDX financials

BDX Forecast & Estimates

18 analysts have analysed BDX and the average price target is 215.76 USD. This implies a price increase of 18.23% is expected in the next year compared to the current price of 182.49.

For the next year, analysts expect an EPS growth of 3.1% and a revenue growth -11.32% for BDX


Analysts
Analysts72.22
Price Target215.76 (18.23%)
EPS Next Y3.1%
Revenue Next Year-11.32%
BDX Analyst EstimatesBDX Analyst Ratings

BDX Ownership

Ownership
Inst Owners94.4%
Ins Owners0.36%
Short Float %2.36%
Short Ratio2.94
BDX Ownership

BDX Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.95200.474B
ISRG INTUITIVE SURGICAL INC48.33174.759B
SYK STRYKER CORP25.22147.128B
BSX BOSTON SCIENTIFIC CORP21.46110.292B
IDXX IDEXX LABORATORIES INC43.8249.757B
EW EDWARDS LIFESCIENCES CORP27.7247.84B
GEHC GE HEALTHCARE TECHNOLOGY16.7338.219B
RMD RESMED INC20.4937.992B
DXCM DEXCOM INC28.9528.573B

About BDX

Company Profile

BDX logo image Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. The company is headquartered in Franklin Lakes, New Jersey and currently employs 72,000 full-time employees. The firm is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

Company Info

BECTON DICKINSON AND CO

One Becton Drive

Franklin Lakes NEW JERSEY 07417 US

CEO: Thomas E. Polen

Employees: 74000

BDX Company Website

BDX Investor Relations

Phone: 12018476800

BECTON DICKINSON AND CO / BDX FAQ

Can you describe the business of BECTON DICKINSON AND CO?

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. The company is headquartered in Franklin Lakes, New Jersey and currently employs 72,000 full-time employees. The firm is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.


What is the current price of BDX stock?

The current stock price of BDX is 182.49 USD. The price decreased by -1% in the last trading session.


Does BECTON DICKINSON AND CO pay dividends?

BECTON DICKINSON AND CO (BDX) has a dividend yield of 2.3%. The yearly dividend amount is currently 4.16.


What is the ChartMill technical and fundamental rating of BDX stock?

BDX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


How is the market expecting BDX stock to perform?

18 analysts have analysed BDX and the average price target is 215.76 USD. This implies a price increase of 18.23% is expected in the next year compared to the current price of 182.49.


What is the GICS sector and industry of BDX stock?

BECTON DICKINSON AND CO (BDX) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


What is the ownership structure of BECTON DICKINSON AND CO (BDX)?

You can find the ownership structure of BECTON DICKINSON AND CO (BDX) on the Ownership tab.